Transgene Announces a New Fundraising Campaign
Transgene, known for its innovative approach to cancer treatment, has initiated a major fundraising venture aiming to collect approximately 105 million euros. This substantial financial effort is primarily focused on expanding their groundbreaking myvac® platform, a key player in personalized cancer immunotherapies.
Details of the Fundraising Campaign
Private Placement and Public Offering
The fundraising strategy involves a dual approach: a private placement directed towards international institutional investors, and a public offering accessible to retail investors via the PrimaryBid platform. This dual-strategy will ensure a wider reach and greater potential for raising the target amount.
Significant Participation from Key Investors
Institut Mérieux, a substantial supporter of Transgene, has committed to invest at least €70 million in this fundraising endeavor. Additionally, two existing shareholders, including the Dassault Group through SITAM Belgium, are anticipated to contribute €10 million towards the private placement. This level of commitment reflects strong investor confidence in Transgene’s strategic direction.
Remarks from Transgene's Leadership
Alessandro Riva, Chairman and CEO of Transgene, emphasized the importance of this fundraising, stating, "This campaign marks a decisive phase for our myvac® platform, which has shown promising results in patients with head and neck cancers. The funds will propel the development of our ongoing trials and facilitate our ambition to create next-generation therapeutic vaccines tailored for patients with early-stage cancers and a high risk of relapse." This underscores the company's commitment to leading advancements in immunotherapy.
Utilizing the Funds Raised
Transgene plans to allocate the net proceeds from this fundraising primarily to advance the myvac® program. The breakdown of the funding will prioritize:
- About 70% to accelerate the myvac® program, focusing on the ongoing Phase 2 trial and additional trials for varied indications.
- R&D costs, particularly for areas outside the myvac® platform, will consume up to 20% of the funds.
- The remaining funds will support general administrative expenses and operational needs, ensuring Transgene maintains a strong position for the upcoming years.
Projected Milestones for the Myvac® Platform
The upcoming period is critical for the development of the myvac® platform, with key milestones anticipated following the fundraising. Notably, initial immunogenicity data and efficacy results are expected between 2026 and 2027. These results will crucially inform the next steps in clinical development, including potential pivotal trials.
Trading Suspension and Future Prospects
As the fundraising efforts proceed, Transgene shares will be suspended from trading on Euronext Paris on the designated closing days. This temporary halt is standard practice to accommodate the logistics of such financial maneuvers. Following the conclusion of the fundraising, trading is scheduled to resume, presenting an opportunity for investors to reassess their positions in light of the new developments.
Lock-up Agreements and Financial Stability
To ensure the stability of share pricing post-fundraising, Transgene, along with TSGH and its board members, has committed to a lock-up period of 90 days following the settlement date. This tactic is intended to bolster investor confidence and minimize immediate selling pressure on the market.
Frequently Asked Questions
What is the purpose of Transgene's fundraising campaign?
The fundraising is aimed at advancing the myvac® platform, a personalized cancer treatment, alongside supporting operational and administrative needs.
Who are the major investors participating in this campaign?
Institut Mérieux is leading the investment with a commitment of €70 million, supported by Dassault Group and others contributing an additional €10 million.
When is the expected closing date for the fundraising?
The private placement and public offering are set to conclude on the 26th of November, with results announced shortly after.
How will the funds be allocated specifically?
Approximately 70% of the funds will expedite the myvac® program, while 20% will cover R&D expenses not directly related to myvac®. The remainder will support general operating costs.
What impact will this fundraising have on existing shareholders?
While any fundraising may involve some dilution, the objective is to enhance company value and operational capability, potentially benefiting shareholders in the long-term growth of the company.
